Plazza Raises US$15M Series A to Scale AI-Powered Pharmacy Network Across India

Aman Priyadarshi, Plazza Founder & CEO

Indian healthtech startup Plazza has secured US$15 million in Series A funding, strengthening investor confidence in AI-driven healthcare infrastructure as demand grows for faster and more reliable access to medicines.

The round was co-led by Accel, Elevation Capital, and Nexus Venture Partners, with participation from existing investors All In Capital and Better Capital. The investment comes less than a year after Plazza raised US$1.4 million in seed funding in September 2025, highlighting strong investor conviction in the company's growth trajectory.

The fresh capital will be used to strengthen Plazza's technology platform, expand its AI-powered inventory intelligence, increase operational capacity, and grow its pharmacy network across India.

Why Did Investors Back Plazza's AI-Powered Pharmacy Model?

Founded in 2024 by Aman Priyadarshi, Bengaluru-based Plazza aims to solve one of India's most persistent healthcare challenges: ensuring prescribed medicines are actually available when patients need them.

India's pharmacy retail market is valued at more than US$30 billion, yet it remains highly fragmented. Independent neighbourhood pharmacies dominate the sector, typically stocking only around 5,000 medicines from an estimated universe of over 100,000 pharmaceutical products.

This fragmented inventory forces many patients to visit multiple pharmacies before completing a prescription—a challenge Plazza believes can be solved through artificial intelligence rather than simply faster delivery.

Priyadarshi said medicine availability should not depend on luck, arguing that pharmacy retail must evolve from shelf-based inventory management to intelligent, technology-driven demand forecasting.

How Does Plazza's AI Inventory Intelligence Work?

Rather than operating as a conventional quick-commerce pharmacy, Plazza uses AI to analyse neighbourhood-level prescribing patterns and recommend which medicines each pharmacy should stock.

Its operating model combines local pharmacy infrastructure with predictive inventory planning, allowing each store to maintain a significantly broader product catalogue.

Key platform capabilities include:

• AI-powered neighbourhood demand forecasting
• More than 40,000 stock keeping units (SKUs) available per outlet
• Over 95% prescription fulfilment rate, compared with the industry average of 50–60%
• Medicine delivery within 15–30 minutes
• Continuous inventory optimisation based on local prescription trends

According to the company, the AI engine continuously analyses prescribing behaviour across neighbourhoods, enabling every outlet to maintain a tailored inventory instead of relying on generic stocking practices.

How Has Plazza Performed Since Launch?

The company says its operational metrics demonstrate strong customer adoption since launch.

Metric	Performance
Founded	2024
Latest Funding	US$15 million Series A
Previous Funding	US$1.4 million Seed (September 2025)
GMV Growth	Nearly 27× between June 2025–March 2026
Average Basket Size	Repeat customers spend ~30% more than first-time buyers
Inventory Per Store	40,000+ SKUs
Prescription Fulfilment	95%+
Industry Fulfilment Average	50–60%
Delivery Time	15–30 minutes

The company also reports that repeat customers place orders with average basket sizes approximately 30% larger than first-time buyers, suggesting increasing customer trust and recurring demand.

What Makes Plazza Different From Quick-Commerce Pharmacy Platforms?

Investors believe Plazza's competitive advantage lies in addressing a structural healthcare problem rather than competing solely on delivery speed.

According to Chirag Chadha, Partner at Elevation Capital, the company's differentiator is its AI-driven inventory intelligence combined with neighbourhood-level demand forecasting, creating a fundamentally different operating model from conventional pharmacy delivery services.

Similarly, Pratik Agarwal, Partner at Accel, noted that Plazza combines deep pharmacy inventory, reliable local fulfilment, 24×7 accessibility, and a consumer-first technology layer to improve the pharmacy experience.

Rather than building additional dark stores, Plazza seeks to improve the efficiency of existing neighbourhood pharmacies through software and predictive analytics.

Why Does This Funding Matter for India's Healthtech Ecosystem?

Plazza's latest financing reflects continued investor interest in healthtech despite a more cautious venture capital environment in 2025–2026.

Across India, investors have increasingly prioritised startups that improve healthcare accessibility, operational efficiency, and affordability using AI and data infrastructure rather than consumer acquisition alone.

The funding also reinforces a broader investment trend led by firms such as Accel, Elevation Capital, and Nexus Venture Partners, which continue backing scalable technology platforms addressing structural inefficiencies in India's healthcare system.

While ecosystem builders such as Hub71 (UAE), Abu Dhabi Global Market (ADGM), and NEOM (Saudi Arabia) have accelerated healthtech innovation across the Middle East, India's healthcare market continues to attract significant venture investment through domestic technology-first models that address large-scale infrastructure gaps.

As AI becomes increasingly embedded into healthcare supply chains, pharmacy inventory optimisation is emerging as a key area where software can directly improve patient outcomes while creating more efficient retail operations.

 

 

FAQs

1. What is Plazza?
Plazza is an Indian healthtech startup founded in 2024 that operates an AI-powered pharmacy retail and rapid medicine delivery platform designed to improve medicine availability through predictive inventory management.

2. How much funding did Plazza raise?
Plazza raised US$15 million in Series A funding, co-led by Accel, Elevation Capital, and Nexus Venture Partners, with participation from All In Capital and Better Capital.

3. How does Plazza's AI technology improve pharmacy operations?
Plazza's AI analyses neighbourhood-level prescribing patterns to recommend optimal inventory for each pharmacy, enabling stores to stock over 40,000 SKUs and achieve 95%+ prescription fulfilment rates.

4. How large is India's pharmacy retail market?
India's pharmacy retail market is estimated to be worth more than US$30 billion, making it one of the world's largest healthcare retail sectors despite its fragmented structure.

5. What will Plazza use the new funding for?
The company will use the Series A capital to expand its technology platform, strengthen AI-powered inventory intelligence, increase operational capacity, and grow its pharmacy network across new Indian markets.